Yahoo
Stockholm - Delayed Quote SEK

Integrum AB (publ) (INTEG-B.ST)

8.30 -0.04 (-0.48%)
At close: October 30 at 12:19:01 PM GMT+1
Chart Range Bar
Loading chart for INTEG-B.ST
  • Previous Close 8.34
  • Open 8.23
  • Bid 8.18 x --
  • Ask 8.30 x --
  • Day's Range 8.16 - 8.36
  • 52 Week Range 6.40 - 11.94
  • Volume 14,139
  • Avg. Volume 46,789
  • Market Cap (intraday) 221.344M
  • Beta (5Y Monthly) 0.42
  • PE Ratio (TTM) --
  • EPS (TTM) -1.45
  • Earnings Date Dec 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. It also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide. The company was incorporated in 1990 and is headquartered in Mölndal, Sweden.

integrum.se

33

Full Time Employees

April 30

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

INTEG-B.ST
22.86%
OMX Stockholm 30 Index (^OMX)
13.47%

1-Year Return

INTEG-B.ST
2.81%
OMX Stockholm 30 Index (^OMX)
17.56%

3-Year Return

INTEG-B.ST
72.43%
OMX Stockholm 30 Index (^OMX)
59.03%

5-Year Return

INTEG-B.ST
89.56%
OMX Stockholm 30 Index (^OMX)
42.80%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 22.33M
Earnings -7.44M
Profit Margin -33.30%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
10M
20M
-40.0%
-35.0%
-30.0%
-25.0%
-20.0%
-15.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -36.27%

  • Return on Assets (ttm)

    -11.81%

  • Return on Equity (ttm)

    -20.75%

  • Revenue (ttm)

    97.9M

  • Net Income Avi to Common (ttm)

    -35.5M

  • Diluted EPS (ttm)

    -1.45

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    15.01M

  • Total Debt/Equity (mrq)

    1.57%

  • Levered Free Cash Flow (ttm)

    -30.15M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: